"The Most Misunderstood Steroid Ever Made" — Dr. Alex Tatem, uploaded 2026-07-12, 22:20, ~87,528 views as of 2026-08-01. Metadata pulled live via
yt-dlp --skip-download --print this session — not from memory. Why this is a YouTube embed, not a self-hosted file: this site's usual recipe (ffmpeg 2-pass compress to under Cloudflare's 25 MiB file limit, self-hosted) works for the ~5–6 minute explainer clips already on this site. At 22 minutes 20 seconds, hitting that size cap would force the bitrate down to a fraction of what those short clips use — visibly blocky video. A clean embed at full source quality serves the reader better than a degraded self-hosted copy. Said plainly here rather than silently substituted.
⚠ Two things to know about this video before you weigh what it says
1. Declared bias, and he prescribes it. The presenter says on camera, in his own words, that he has an "unashamed bias" toward nandrolone — and that he prescribes it in his own practice. That doesn't make his information wrong; the mechanism and history claims below check out independently against PubMed, the FDA, and the DEA. But it means the source is a treating physician describing a compound he likes and personally sells access to, not a neutral reviewer, and that's worth knowing before you weigh his conclusion.
2. The video is a paid Rugiet ad, and he's joining their board. This video is sponsored by Rugiet, a TRT telehealth company, and partway through he announces he is joining Rugiet's medical advisory board — while explaining that "the only sane way to run" nandrolone is on a testosterone base, which is the exact product a TRT clinic prescribes. We could not find any FTC or FDA enforcement action naming Rugiet specifically in our search. For context: a comparable telehealth hormone/ED company, Hims & Hers, was sued by the FTC for deceptive practices and privacy violations on 2026-07-29 — about two and a half weeks AFTER this video posted — so the whole telehealth-hormone sector is under fresh regulatory scrutiny, not just this one company. Rugiet's own "grown 400% in 2 years" claim is the company's marketing, unverified by us either way.
Every claim from the video below is labeled as his claim and checked independently against PubMed, the FDA, the DEA, and WADA — where the published literature disagrees with him, or goes further than he does, that's stated plainly rather than smoothed over.
1962
FDA Approved As A Medicine
Approved for the anemia of kidney failure. The original approval has never been withdrawn for safety or effectiveness — FDA's own 2010 determination confirms it, verbatim, below.
0
US Manufacturers Today
Organon stopped marketing it in 2002; the last generic maker (Watson) stopped production in 2007 over raw-material supply. Every legal dose in the US now comes from a compounding pharmacy.
20 RCTs
Real Placebo-Controlled Human Trials
An unusually strong human evidence base for a compound this site covers — osteoporosis, HIV wasting, and dialysis all have real, published RCTs behind them. Two separate meta-analyses sit behind that: Prokopidis 2026 pooled 20 RCTs across all indications, and Camara 2025 pooled 7 osteoporosis RCTs totalling 293 participants. They are different papers and are not added together anywhere on this page.
Schedule III
DEA Controlled Substance
WADA-banned at all times, in and out of competition. Metabolites detected 4–9 months after a single injection in a controlled study.
What Is Nandrolone?
PubMed T1
Nandrolone (19-nortestosterone) is testosterone with one atom removed — delete the methyl group at carbon-19 and you get nandrolone. Chemist Arthur Birch first synthesized it in 1950; trenbolone, from the same "19-nor" family, wasn't synthesized until 1963 — nandrolone really is the older compound, and his claim checks out. Organon brought it to market in 1962 as Deca-Durabolin, with FDA approval for the anemia of kidney failure — a real, on-the-books medical approval, not a research chemical.
Anabolic:Androgenic Ratio
~11:1 (Rat Model)
In the classic Hershberger rat assay — the standard test weighing muscle-building action against prostate/androgenic stimulation — testosterone scores a reference index of ~1 and nandrolone decanoate scores roughly 10.6–12.1, i.e. about 11 times more tilted toward muscle than androgen effects. This is his number, and it holds up against the actual pharmacology literature — but it's a rat number from castrated immature rats, not a human measurement, exactly as he flags it himself.
→ PMID 18500378 (Kicman AT, Br J Pharmacol, 2008)
5-Alpha-Reductase — Runs Backward
Down In Muscle, Up Elsewhere
The enzyme 5-alpha-reductase converts testosterone into DHT, a stronger androgen — that's what drives prostate growth and hair loss. It does the opposite to nandrolone: its 5-alpha-reduced metabolite binds the androgen receptor more weakly than nandrolone itself, and human skeletal muscle has no detectable 5-alpha-reductase activity at all — so muscle gets nandrolone at full strength while DHT-dependent tissue gets a diluted signal. The mechanism, precisely as he describes it.
→ PMID 18500378 (same review, muscle-tissue enzyme-activity data)
Progesterone Receptor Activity
Real, Less Quantified
Nandrolone belongs to the 19-nor steroid class, which the pharmacology literature notes carries progestational activity — a plausible route to the gynecomastia/libido/mood complaints some users report, alongside its low direct estrogen conversion. This piece of the mechanism is genuine but noticeably less rigorously quantified in the peer-reviewed literature than the androgen-receptor/5-AR story above — flagged honestly rather than overstated.
→ PMID 18500378 (19-nor progestational note) · PMID 27141449 (Pan & Kovac review)
DHT Dependence — The Trade-Off
Same Mechanism, Opposite Cost
The exact biochemistry that spares nandrolone's hairline and prostate is what can break erections without a testosterone base: firm, nitric-oxide-driven erections depend on DHT, and nandrolone alone starves that pathway. This is the mechanistic root of "deca dick" — covered at full length, at the same visual weight as the joint and muscle benefits, in the safety section below.
→ cross-reference this page, §9b Side Effects & Who Should Be Careful
Evidence Stack: Where the Real Data Actually Sits
PubMed · 20 RCTs (2026 meta-analysis)
Nandrolone is unusual for this site: it has a real, multi-decade human RCT record. The honest gap isn't a lack of trials overall — it's that the one use case the internet cares about most (joints) has zero placebo-controlled backing, while the boring, FDA-relevant uses (osteoporosis, wasting, dialysis) have plenty.
What the Animal Models Actually Show — Joints Specifically
PubMed · Animal / Preclinical
The "nandrolone helps joints" claim splits into two very different findings depending on where the drug goes. This is the exact nuance the forums leave out.
Sheep Model — Muscle Preserved
Fatty Infiltration Blocked
In sheep with a surgically detached rotator cuff, starting nandrolone at the time of injury measurably blocked the surrounding muscle from atrophying and turning to fat during healing — a genuine, real finding.
→ PMID 27523963 (Flück et al, J Steroid Biochem Mol Biol, 2017)
Sheep Model — Timing Matters
Muscle Stops Responding After Retraction
A separate sheep study found that once a torn rotator cuff muscle has fully retracted, it stops responding to anabolic steroids altogether — the muscle has to still be biologically "reachable" for nandrolone to do anything.
→ PMID 23024152 (Gerber et al, Am J Sports Med, 2012)
Rabbit Model — Direct Tendon Injection
Healed Worse, Weaker
When nandrolone was injected directly into the repaired tendon rather than given systemically, the tendon showed less fibroblastic (healing) activity and less biomechanical strength than tendons that got no steroid at all. The study's own conclusion: local nandrolone acts as a "healing inhibitor" on tendon.
→ PMID 20690845 (Papaspiliopoulos et al, J Invest Surg, 2010) — this is the specific study behind his "injected straight into the tendon, healed worse" claim, and it checks out exactly.
The honest read: nandrolone's joint benefit, where it's real, appears to work by protecting the muscle around an injured joint from wasting — not by rebuilding cartilage or strengthening tendon. Put it directly into the tendon and the animal data says it actively makes healing worse. That distinction — muscle vs. tendon — is exactly what most "deca fixed my shoulder" forum posts don't know to ask about. If tendon/ligament healing itself, rather than surrounding muscle, is the actual goal, this site's BPC-157 and TB-500 pages cover peptides studied more directly for that — with their own, separate evidence gaps.
Published Human Trials — the Actual Numbers
PubMed · Human RCT
This is the load-bearing section. Every claim below is the actual trial result, not a marketing summary of it — including his own study, with its limits stated at the same size as its headline number.
| # | Study / PMID | Population | n | Result | Outcome |
|---|---|---|---|---|---|
| 1 | Frisoli et al · PMID 15972619 — 2-yr double-blind, placebo-controlled RCT | Postmenopausal osteoporosis (elderly women) | 65 | Lumbar spine + femoral neck BMD up 3–5% vs. baseline; new vertebral fractures 21% (ND) vs. 43% (placebo); lean mass up ~12% at 2 yrs; hemoglobin up 14%. | Beat placebo |
| 2 | Need et al · PMID 8461566 — double-blind placebo-controlled RCT | Established osteoporosis | Not stated in abstract | One of the earliest placebo-controlled ND osteoporosis trials; folded into the 2026 meta-analysis below. | Included in meta-analysis |
| 3 | Gerritsma et al · PMID 8174308 — 1-year prospective controlled study | Postmenopausal women, osteoporosis + HRT | Not stated in abstract | Measurably lower voice pitch, loss of high frequencies, and increased vocal instability vs. HRT-alone controls — voice virilization is not a rumor, it was directly measured. | Documented harm |
| 4 | Camara et al · PMID 41477377 — systematic review + meta-analysis, 7 RCTs | Postmenopausal osteoporosis | 293 | Fracture risk reduced (moderate certainty); BMD up modestly; muscle mass and pain improved. Virilizing adverse events significantly more common than placebo (RR 4.59), mostly mild and reversible. | Real benefit + real AE rate |
| 5 | Gold et al · PMID 16494628 — RCT vs. placebo and testosterone | HIV-associated wasting | 303 | Nandrolone decanoate outperformed testosterone on weight gain in HIV wasting — matches his "beat the gold standard" claim exactly. | Beat testosterone |
| 6 | Johansen et al · PMID 10208142 — RCT, JAMA 1999 | Hemodialysis patients | 29 | Anabolic effects (lean mass) confirmed in a randomized trial — the same anemia-of-renal-failure population the drug was originally approved for. | Beat placebo |
| 7 | Johansen et al · PMID 16825332 — RCT, JASN 2006 | Hemodialysis + resistance exercise | 79 | Nandrolone plus resistance training improved body composition and muscle function vs. exercise alone. | Beat exercise-alone |
| 8 | Prokopidis et al · PMID 41936385 — 2026 systematic review + meta-analysis, 20 RCTs | Adults (mixed indications) | k=11–12 per outcome | Lean soft tissue up (+1.59 kg, p<0.01) reliably. Handgrip strength (p=0.10), knee-extension strength (p=0.99), and most BMD sites: not significantly different from placebo. Authors' own conclusion: findings "do not support routine clinical use... for improving musculoskeletal health." | Mass up, strength/BMD not proven |
| 9 | Tatem et al (the presenter's own study) · PMID 32257859 — uncontrolled pilot | Hypogonadal men, joint pain, on testosterone | 48 enrolled / 18 (37.5%) completed follow-up | 13 of 18 (72.2%) reported marked joint-pain improvement; pain scores fell ~52% on average; 5 of 18 cut back pain medication. No placebo group. No blinding. Self-selected participants. Median dose 110 mg over a median 62-day course. | Real signal, no control arm |
Reality check (honest reading): Nandrolone's osteoporosis, HIV-wasting, and dialysis trials are real, randomized, and placebo-controlled — genuinely strong evidence by this site's usual standard. But the specific use case driving most of today's interest — joint pain in gym-going men on TRT — has exactly one published data point, and it's the presenter's own 48-patient pilot with a 62.5% dropout rate, no control group, and no blinding. He says this himself on camera before the comments can. Both things are true at once: the drug has an unusually solid RCT record overall, and the specific reason most people are watching that video has almost no controlled evidence behind it at all.
Cost — the Drug and Its Real Alternatives
Market / T4
Nandrolone competes against very different alternatives depending on why someone's taking it — joint pain has its own cost landscape, and so does the anemia indication it was originally approved for.
Nandrolone Decanoate (Compounded)
~$18
per 200 mg/1 mL vial · GoodRx-tracked generic price
At 50–100 mg/week, roughly $20–35/month for the drug alone — plus the compounding pharmacy's dispensing fee and a prescriber visit
Testosterone Cypionate (Required Base)
$30–60
per month, compounded — not optional if running nandrolone per his own protocol
The real all-in cost of "just add a little Deca" includes this second prescription, every month, indefinitely
Most Evidence — Joints
Corticosteroid Joint Injection
$100–600
per injection, cash-pay, office-based
Decades of RCT evidence for joint pain specifically — the actual "most evidence" option for this use case, unlike nandrolone's uncontrolled pilot
Physical Therapy
$75–250
per session, cash-pay
A typical course runs 6–12 sessions; the only joint-pain option here with decades of RCTs behind it and zero fertility or cardiac risk
Unregulated / No Verified Price
NPP (Black Market Only)
N/A
no legal US channel, no verifiable pricing, no purity or dosing oversight
Unlike the decanoate ester, NPP has no compounding-pharmacy pathway in the US — it exists only through the same illicit channels as any other black-market steroid. We are not printing a price for it, because none of the numbers online are independently verifiable and doing so would imply a confidence in a black-market product this page does not have.
→ No citable source; deliberately not estimated
💰 Follow the Money — Precisely Stated
This is a cheap, off-patent, no-manufacturer drug — the opposite of a pharma-marketing story. Nandrolone decanoate costs roughly $18 per 200 mg vial through GoodRx-tracked compounding channels. No company holds a patent on it, no company currently manufactures the branded product in the US, and there is no one positioned to fund a large, modern, placebo-controlled trial specifically on the joint-pain use case that actually drives demand today. That is exactly why the only joint-pain data that exists is one urologist's self-funded, uncontrolled 48-patient pilot — not because anyone tested it properly and it failed, but because nobody with capital has a reason to run the trial. State the precise version: "no controlled joint-pain trial exists" is a funding gap, not a proven negative.
Where the money runs the other direction: the video recommending it is sponsored by a TRT telehealth company (Rugiet) that profits directly from selling the testosterone base the presenter says is mandatory to run nandrolone safely. That is a real, disclosed incentive to make the "add a little Deca to your TRT" framing sound more settled than the joint-pain evidence actually is — precisely stated: a financial interest in more testosterone prescriptions, not proof that any specific claim in the video is false.
Researched Protocol Patterns
Trial Dose
Community / Clinic
Nandrolone decanoate is an oil-based, pre-mixed injectable — it ships already dissolved at a labeled concentration and is never reconstituted with bacteriostatic water the way a lyophilized peptide is. A calculator that asked "how much water did you add" would be actively wrong and unsafe for this drug. The patterns below are shown for context; the working dose tool for this page uses a concentration/oil-based model instead of the site's shared peptide reconstitution calculator (see the engineering note at the end of this section).
RCT Dose Range (Osteoporosis)
~50 mg / 3 wks
The Frisoli 2005 trial dosed 50 mg intramuscularly every 3 weeks — roughly 17 mg/week averaged out, far below what bodybuilders use, and the dose behind the real BMD/fracture-reduction data above.
TRIAL DOSE
Modern TRT-Clinic Pattern
50–100 mg/wk
The pattern he describes as the modern telehealth-era norm: low-dose nandrolone stacked on a testosterone base, rather than nandrolone alone. Consistent with what independent TRT-focused physicians (see §9 below) also describe as common current practice. Men on this kind of TRT+Deca stack sometimes add a third drug, an aromatase inhibitor, to manage estradiol — see this site's aromatase inhibitors page for that separate, also off-label, decision.
CLINICAL PRACTICE
His Own Pilot Study Dose
~110 mg / 62 days
Median dose and duration in the presenter's own uncontrolled joint-pain pilot (PMID 32257859) — shown here as the actual number behind the 72% improvement figure, not a rounded community estimate.
HIS PILOT (UNCONTROLLED)
Bodybuilding-Scale Dosing
300–600+ mg/wk
Doses reported at this scale are 3–12× the modern clinical pattern above and fall outside any RCT ever run. This is also the dose range where the cardiac, fertility, and hematocrit risks in the safety section below become most concrete — not a "just take more for better results" scaling.
UNSUPERVISED / HIGH RISK
Why the calculator below asks what it asks: nandrolone decanoate ships as an oil already mixed to a strength printed on the label — usually 100, 200 or 250 mg/mL. There is nothing to reconstitute and nothing you should ever add to the vial, which is why the calculator asks for the concentration on your label rather than for water you added. If a dosing tool ever asks you how much bacteriostatic water you mixed into an oil, it is the wrong tool for this drug.
Regulatory Position (August 2026)
T1 · Primary Documents
Nandrolone's regulatory story is a genuinely unusual combination: a real, never-revoked FDA approval, a hard Schedule III controlled-substance status, and a total absence of any current US manufacturer.
FDA — August 10, 2010 Determination
Not Withdrawn for Safety
FDA's own primary document states: "DECA-DURABOLIN (nandrolone decanoate) Injection... was not withdrawn from sale for reasons of safety or effectiveness." NDA 13-132, held by Organon, was "initially approved on October 5, 1962." Organon notified FDA on May 21, 2002 that it was no longer marketing the product; it moved to the Orange Book's Discontinued Drug Product List for business reasons, and a new manufacturer's ANDA could still be approved today if one applied.
→ Federal Register, primary document
→ Federal Register, primary document
DEA — Schedule III (Anabolic Steroid Control Acts, 1990/2004)
Controlled Substance, Legitimate Medical Use
DEA's own October 2025 fact sheet lists nandrolone decanoate among "the main anabolic steroids currently prescribed in the United States," alongside testosterone, methyltestosterone, and oxandrolone — for "testosterone deficiency, delayed puberty, anemia, breast cancer, and AIDS-related tissue wasting." Separately, DEA's own class-wide adverse-effects language: "In women, use can induce permanent physical changes, including deepening of the voice, increased facial and body hair growth, and lengthening of the clitoris. In men, use can cause shrinkage of the testicles... and sterility."
→ DEA Diversion Control Division fact sheet, primary document (Oct 2025)
→ DEA Diversion Control Division fact sheet, primary document (Oct 2025)
WADA — Prohibited At All Times
S1.1, Named Explicitly
The 2026 WADA Prohibited List, Section S1.1 (Anabolic Androgenic Steroids), states this class is "Prohibited at all times (in- and out-of-competition)" and names "Nandrolone (19-nortestosterone)" explicitly. A controlled excretion study found metabolites detectable at 4 months in 6 of 11 men and at 9 months in 3 of 11 after a single 150 mg dose — the real basis for the "6–9 month" detection guidance, individually variable.
→ WADA Prohibited List 2026, primary document · → PMID 26853157 (detection window study)
→ WADA Prohibited List 2026, primary document · → PMID 26853157 (detection window study)
Compounding Pharmacy Channel
Legal, But Batch-by-Batch Oversight Only
Because no NDA/ANDA holder currently markets the product, every legal US dose is compounded to prescription by a 503A pharmacy — legal, but without the FDA's routine finished-product oversight a manufactured drug gets. NPP (nandrolone phenylpropionate), by contrast, has no legal compounding pathway in the US at all and exists only on the black market — a genuinely different legal position from the decanoate ester covered on the rest of this page.
→ FDA 503A bulk substances page
→ FDA 503A bulk substances page
PubMed vs. The Doctors
T-Doc · Named Practitioners
PubMed
Two equal pillars — the controlled trial record above, set against three credentialed, independently verified physicians who've each addressed nandrolone on the record, and who do not all agree with each other.
📚 What the Controlled Trials Show
Real, randomized, placebo-controlled evidence exists in three areas: postmenopausal osteoporosis (BMD up, fractures 21% vs. 43%), HIV-associated wasting (beat testosterone on weight gain), and dialysis (lean mass up; the haemoglobin rise is reported in the osteoporosis trials, not these) — a genuinely strong RCT record for this site.
The 2026 meta-analysis (20 RCTs) found lean tissue reliably increases, but handgrip strength, knee-extension strength, and most bone-density sites did not reliably improve — a materially more cautious verdict than "it builds strength and bone," and more cautious than the presenter's own framing in places.
Zero placebo-controlled trials exist for the specific joint-pain-in-gym-goers use case. The only data point is the presenter's own 48-patient, no-control, no-blinding pilot with a 62.5% dropout rate — a real signal, but not proof.
Virilizing adverse events in women are a documented, statistically significant finding (RR 4.59 vs. placebo) — mostly mild and reversible per the meta-analysis, but real and measured, not internet exaggeration.
🩺 What Practitioners Report
Dr. Alexander J. Tatem, MD — board-certified urologist, American Board of Urology; residency, Indiana University School of Medicine; fellowship, Baylor College of Medicine (male fertility, microsurgery, sexual medicine). Credential independently verified via Urology of Indiana's own physician page, Ascension, and Doximity. This is the presenter, and also the author of the one published joint-pain pilot (PMID 32257859) — a genuine Pass-3 finding: a licensed clinician who treated real patients and published the honest, uncontrolled result, dropout rate included. Declares an "unashamed bias" and prescribes nandrolone himself (see disclosure above); this video is Rugiet-sponsored and he is joining Rugiet's medical advisory board.
Dr. Thomas O'Connor, MD ("The Anabolic Doc") — board-certified internal medicine (American Board of Internal Medicine, since 2005), Clinical Instructor of Medicine, University of Connecticut School of Medicine; author, America on Steroids: A Time to Heal. Credential independently verified via his own practice page and Testosteronology.com. "Testosterone + Deca-Durabolin — Harm Reduction" (2020-08-04, 17:57, 255,111 views). Takes a notably more cautious position than the presenter above: he states outright that he counsels most men to avoid testosterone+Deca, and frames his content as harm reduction "should they choose to use it despite the risks" — covering the sexual side effects, blood pressure, heart, prostate, and fertility risk directly. Discloses a commercial interest: runs a paid TRT/"Anabolic Recovery" consult practice and a subscription health app.
Dr. Rand (Randolph) McClain, DO — board-certified, regenerative & sports medicine, Santa Monica, CA; residency, Keck Medicine of USC. Credential independently verified via Healthgrades, BoardCertified.com, and Zocdoc (independent third source; not hyperlinked here — Zocdoc's bot-detection returned an automated-check 403 this session despite being a real, readable listing in a browser). "Nandrolone | Anabolic Steroids with Dr. Rand McClain" (Mind Pump TV, 3:15, 125,986 views). Discusses nandrolone's use pattern in TRT-adjacent care. Discloses a commercial interest: the video promotes a hormone-therapy partnership between his clinic and the Mind Pump media brand.
Real-World Use
Outside its narrow FDA indication, the people actually using nandrolone today split into two very different groups: men on telehealth TRT adding a low dose for joints or lean mass, and unsupervised users running bodybuilding-scale doses (300 mg/week and up) they source outside a prescription. The three physicians above agree on the mechanism and the DHT-dependence trade-off; they disagree sharply on how comfortable to be recommending it, from Tatem's "compelling tool... low monitored dose is defensible" to O'Connor's default advice to avoid the combination altogether. That disagreement, between two board-certified physicians who both treat this population, is itself useful information for a reader trying to decide.
Removal asymmetry — Pass 8 note: Our
yt-dlp "ytsearch8:nandrolone deca durabolin doctor explains joint pain TRT" search returned eight results, all currently live, from 2016–2025, spanning a licensed internist, a licensed DO, an anonymous "harm reduction" channel, and general-audience fitness content. No evidence of a removal or demonetization campaign against physician-led nandrolone content was found — bounded to this single search session; we report the absence honestly rather than assuming a suppression pattern that this search didn't turn up.
Side Effects & Who Should Be Careful
DEA / PubMed · Primary Sources
These get the same visual weight as the joint and lean-mass benefits above — not a footnote. Nandrolone is genuinely gentler than most anabolic steroids on several fronts (it's an injected oil, so it skips oral-steroid liver toxicity; its mild androgenic profile means less acne and hair loss) — and genuinely capable of real, lasting harm on others.
"Deca Dick" — Erectile Dysfunction
DHT-Dependence Mechanism
The same 5-alpha-reductase quirk that spares nandrolone's hairline starves DHT-dependent erectile function when nandrolone is run without a testosterone base. This is the mechanistic reason the presenter (and every physician cited above) says a testosterone base is not optional — it's the harm-mitigation step for a real, common, well-documented risk.
→ §2 mechanism above; DEA fact sheet, general androgen-pathway adverse effects
Fertility / HPG Axis Shutdown
Real, Can Be Permanent With Abuse
Like all exogenous anabolic-androgenic steroids, nandrolone suppresses the pituitary's LH/FSH signaling to the testicles. DEA's own fact sheet: "In men, use can cause shrinkage of the testicles... and sterility." This is why every physician cited on this page, including the one who prescribes it, singles out young men who still want children as people who should not use it.
Cardiac Risk — Genuinely Uncertain
Unsettled, Stated Precisely
Animal studies showing clear heart damage generally used doses around 20× clinical human doses. Separately, long-term unsupervised abusers (high, unmonitored, often multi-drug regimens) show measurably higher rates of cardiomyopathy and heart failure in the observational literature. The precise, honest statement: controlled trials at low, monitored, clinical doses are too small and too short to settle whether that same risk applies at 50–100 mg/week — this is a real evidence gap, not a "proven safe" or "proven dangerous" finding either way.
→ PMID 20020375 (Vanberg & Atar, cardiovascular review) · PMID 33477800 (Albano et al, AAS adverse effects review)
Virilization in Women
Documented, Mostly Mild
DEA's own language: "deepening of the voice, increased facial and body hair growth, and lengthening of the clitoris." The 2025 osteoporosis meta-analysis (Camara, Cureus 2025 — not the 2026 all-indication one) found virilizing adverse events significantly more common on nandrolone than placebo (RR 4.59) — "low certainty" evidence, described as "mostly mild" and generally reversible on stopping, but real and separately measured in a dedicated voice study (Gerritsma 1994), not internet exaggeration. We could not independently verify a precise "~50% of women" figure from any single accessible source — treat his round number as directionally consistent with, but not literally sourced to, one confirmed study.
Hematocrit Rise
Flip Side of the Anemia Benefit
The same red-blood-cell stimulation that makes nandrolone useful for anemia raises hematocrit in people who don't need more red blood cells — thickened blood that needs monitoring via routine bloodwork, same as any TRT protocol.
→ mechanism consistent with FDA's original anemia indication; monitor via standard CBC
Cholesterol — HDL Down, LDL Often Up
The Most Consistent Lab Change In This Drug Class
This is the change that shows up most reliably across anabolic-androgenic steroids, and the cardiovascular review cited above states it plainly: "The most prominent changes are concomitant elevations of LDL and decreases of HDL, effects that increase the risk of coronary artery disease." It is worth separating from the "cardiac risk is uncertain" card above, because it is not uncertain — the lipid shift is measurable on an ordinary blood test long before anything shows up as a symptom. If you have existing coronary artery disease, this is the single number to put in front of your cardiologist before anything else.
The drug's own FDA labeling says the same thing independently, and more bluntly — WARNINGS, in capitals: "BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS AND ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEIN AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEIN. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE." Two independent sources, one of them the manufacturer's own required labeling. Note the label says HDL decreased but LDL only sometimes increased — the HDL drop is the consistent half. This is the least uncertain harm on this page.
→ PMID 20020375 (Vanberg & Atar, cardiovascular review) · DailyMed SPL a586b484, WARNINGS, retrieved and quoted verbatim
What A Monitoring Doctor Would Actually Pull
Baseline, Then On A Schedule
"Get bloodwork" is not an instruction until someone names the tests. A prescriber monitoring this compound is generally looking at: a full lipid panel (LDL and HDL, per the card above); CBC/hematocrit for blood thickening; LH and FSH plus total testosterone to see how far your own production has been suppressed; estradiol, since nandrolone's progesterone-side activity produces breast-tissue and libido effects people routinely misattribute to estrogen; PSA and a prostate exam in older men on any androgen; blood pressure at every visit; and liver and kidney panels at baseline. Bring this list to the appointment rather than asking for "a steroid panel," which is not a thing labs offer.
→ standard androgen-monitoring practice; lipid rationale PMID 20020375, hematocrit per the card above. Your prescriber sets the actual schedule.
Hard Contraindications & The Legal One
Not Judgment Calls
These are the four contraindications in nandrolone decanoate's own FDA labeling, quoted from it rather than summarized: "Male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate. Carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. Pregnancy, because of masculinization of the fetus. Nephrosis or the nephrotic phase of nephritis."
The third one deserves singling out on a page built substantially on women's osteoporosis trials: the drug that was studied for building bone is contraindicated in a woman whose breast cancer is already dissolving it. These are not risk-benefit conversations. They are stop signs.
And the one people forget entirely: as a schedule III controlled substance, possessing nandrolone in the United States without a valid prescription is a federal crime. The compound being FDA-approved and legitimately prescribable does not make a vial bought from a dealer legal to hold.
The third one deserves singling out on a page built substantially on women's osteoporosis trials: the drug that was studied for building bone is contraindicated in a woman whose breast cancer is already dissolving it. These are not risk-benefit conversations. They are stop signs.
And the one people forget entirely: as a schedule III controlled substance, possessing nandrolone in the United States without a valid prescription is a federal crime. The compound being FDA-approved and legitimately prescribable does not make a vial bought from a dealer legal to hold.
→ DailyMed SPL a586b484 — nandrolone decanoate labeling (Watson, 2007), CONTRAINDICATIONS, retrieved and quoted verbatim · DEA Diversion Control Division fact sheet for scheduling
Coming Off — Nobody Can Give You A Timeline
Recovery Is Real But Unpredictable
Because nandrolone suppresses the LH/FSH signal from your pituitary, stopping does not immediately restart your own production. Recovery of the hypothalamic-pituitary-gonadal axis varies enormously between people and with how long and how heavily the compound was run — which is exactly why the physicians cited on this page steer young men who want children away from it entirely. Anyone telling you a confident number of weeks for your own recovery is guessing. Separately, and unrelated to how you feel: its metabolites remain detectable for months (see the drug-testing section), so "I stopped, I'm clear" is false for a tested athlete long after the drug stops doing anything.
→ HPG-suppression mechanism per the fertility card; detection window PMID 26853157
"Injected Oil, Not Oral" — True, And Much Narrower Than It Sounds
Read This Beside The Label, Not Instead Of It
The genuine part: because it is an injectable oil rather than a 17-alpha-alkylated oral tablet, nandrolone skips the first-pass liver toxicity that makes oral anabolic steroids comparatively harder on the liver. Its milder androgenic profile also means less acne, less male-pattern hair loss and less prostate stimulation than testosterone itself, dose for dose. Those are real advantages and they are why it gets called the gentle one.
But "gentler on the liver than an oral" is not "safe for the liver," and nandrolone's own FDA labeling opens its WARNINGS section with a different emphasis. Quoted in full, with nothing cut, because every clause in it matters and in both directions: "PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS. LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR."
Two caveats on that quote, both in nandrolone's favour, because leaving them out would be its own kind of dishonesty. First, the label itself says most often benign, and says lesions usually disappear and tumors often regress when the drug is withdrawn. An earlier draft of this card cut those clauses and it made the warning sound worse than the document it came from. Second, this is androgen-class labeling — the same class-wide language the DEA fact sheet uses elsewhere on this page — and the hepatic events it describes are predominantly associated with 17-alpha-alkylated oral steroids, which nandrolone is not. We found no nandrolone-specific human hepatic-tumor literature to cite here, and we are not going to imply one exists.
So the honest version is neither "the liver is fine" nor "this drug gives you liver tumors." It is: on this drug the liver is a monitored organ, not an ignorable one — which is why a liver panel sits on the baseline list in the monitoring card.
But "gentler on the liver than an oral" is not "safe for the liver," and nandrolone's own FDA labeling opens its WARNINGS section with a different emphasis. Quoted in full, with nothing cut, because every clause in it matters and in both directions: "PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS. LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR."
Two caveats on that quote, both in nandrolone's favour, because leaving them out would be its own kind of dishonesty. First, the label itself says most often benign, and says lesions usually disappear and tumors often regress when the drug is withdrawn. An earlier draft of this card cut those clauses and it made the warning sound worse than the document it came from. Second, this is androgen-class labeling — the same class-wide language the DEA fact sheet uses elsewhere on this page — and the hepatic events it describes are predominantly associated with 17-alpha-alkylated oral steroids, which nandrolone is not. We found no nandrolone-specific human hepatic-tumor literature to cite here, and we are not going to imply one exists.
So the honest version is neither "the liver is fine" nor "this drug gives you liver tumors." It is: on this drug the liver is a monitored organ, not an ignorable one — which is why a liver panel sits on the baseline list in the monitoring card.
→ §2 mechanism above · DailyMed SPL a586b484 — nandrolone decanoate labeling (Watson, 2007), WARNINGS section retrieved and quoted directly
⛔ Who this page's own cited physicians say should avoid it: young men with normal testosterone who still want biological children (fertility risk, stated by every physician cited); anyone with a significant cardiac history without a full cardiac workup first (echo, coronary calcium score, or stress test — the presenter's own recommendation) plus a baseline lipid panel, since HDL falls and LDL often rises on this drug class; anyone running it without a monitoring physician at all; and women, outside a supervised medical trial context, given the documented virilization risk — and per the drug's own labeling, anyone with prostate or breast carcinoma, anyone pregnant or who might become pregnant, and anyone with nephrosis, without exception.
✓ What's reassuring, stated plainly: at the studied clinical doses (50–100 mg/week, monitored, on a testosterone base), the reported cardiac and hematologic event risk appears low — the honest gap is that nobody has run the large, long trial that would let anyone say that with real confidence, not that the drug has been proven risky at that dose. Read it alongside two things above, though: the label's own WARNINGS on liver lesions, and the lipid card — the LDL-up / HDL-down shift is not part of the uncertainty, it is the one change you should expect to see on a blood test.
The Bottom Line — In Plain English
An honest read of nandrolone in 2026
What it is: A 1962 FDA-approved anabolic steroid — testosterone with one methyl group removed — originally approved to treat the anemia of kidney failure. No US company currently manufactures it; every legal dose comes from a compounding pharmacy on prescription. It is chemically the same family as trenbolone but arrived 13 years earlier and, unlike tren, has a real multi-decade human RCT record behind it.
Who's using it: Two very different groups. Telehealth TRT patients adding a low dose (50–100 mg/week) on a testosterone base for joints or lean mass, under a prescriber's monitoring — and unsupervised users running 3–12× that dose sourced outside any prescription, where most of the real cardiac and fertility harm in the literature actually shows up.
What the law says: A genuinely approved, never-safety-withdrawn FDA drug that is simultaneously a Schedule III controlled substance and permanently WADA-banned. NPP, the short-acting version, has no legal path in the US at all — decanoate and NPP are the same molecule family in two very different legal positions.
What the research shows: Real, randomized, placebo-controlled evidence for osteoporosis, HIV wasting, and dialysis — an unusually strong record for a compound like this. The specific "fixes my joints" claim driving most current interest has zero placebo-controlled trials behind it, only one physician's honestly-reported, uncontrolled 48-patient pilot. A 2026 meta-analysis found lean tissue reliably increases but strength and bone density mostly do not — a more cautious verdict than the internet's reputation for the drug.
- Three real RCT-backed uses exist (osteoporosis, HIV wasting, dialysis) — genuinely strong evidence for this site's usual bar.
- Zero placebo-controlled trials exist for joint pain specifically — the internet's #1 reason to use it has the thinnest evidence on this page.
- Fertility loss, "deca dick," virilization in women, and unresolved cardiac risk are documented, real, and get equal billing with the upside here — not an afterthought.
- The presenting physician discloses an "unashamed bias," prescribes the drug himself, made this video as a paid Rugiet ad, and is joining Rugiet's medical advisory board — all stated plainly, near the video, because it changes how to weigh his framing.
- A second board-certified physician (O'Connor) reviewing the identical combination counsels most men to avoid it — real, documented disagreement between credentialed doctors, not a settled consensus.
- Not medical advice. Schedule III, prescription-only, and genuinely risky if run without a monitoring physician — talk to your own doctor, not a YouTube video, before using it for anything.